Evaluation of P-Glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in Primary Tumor and Metachronous Lung Metastases in Patients with High-Grade Osteosarcoma

Stefano Ferrari, Franco Bertoni, Licciana Zanella, Elisabetta Setola, Patrizia Bacchini, Marco Alberghini, Michela Versari, Gaetano Bacci

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND. Investigation of the relation between primary tumor and metastatic disease is necessary for the identification of predictive factors for postrecurrence survival (PRS) in patients with recurrent osteosarcoma. METHODS. Cellular levels of P-glycoprotein, ErbB-2, p53, and Bcl-2 expression were evaluated in primary tumor biopsy and metachronous pulmonary metastasis specimens from 19 patients with high-grade osteosarcoma. Results were analyzed for differences between primary tumor and pulmonary metastases and for correlations between expression patterns and survival. RESULTS. Positive staining in lung metastases was noted in 68%, 53%, 32%, and 84% of patients for P-glycoprotein, ErbB-2, p53, and Bcl-2, respectively. These percentages were higher than those observed in primary tumor specimens for all genetic markers evaluated, with a significant difference in the percentage of patients with positive staining for P-glycoprotein (68% vs. 32%; P = 0.05) and a near-significant difference in the percentage of patients with positive staining for Bcl-2 (84% vs. 53%; P = 0.08). Patients with ErbB-2 expression in the primary tumor were more likely to have multiple metastases and shorter recurrence-free intervals compared with patients in whom ErbB-2 expression was not observed, whereas differences in P-glycoprotein, p53, and Bcl-2 expression were not related to differences in metastatic pattern. PRS was influenced by p53 expression levels in pulmonary metastases, with patients who had negative staining for p53 having a significantly better PRS rate relative to patients with positive staining for p53 (3-year PRS rate: p53-negative, 64%; p53-positive, 17%; P = 0.008). CONCLUSIONS. In the current study of patients with high-grade osteosarcoma, most patients exhibited increased cellular expression of P-glycoprotein, ErbB-2, and Bcl-2 in recurrent pulmonary metastases compared with primary tumor. Further studies aimed at investigating the relation between altered p53 expression in lung metastases and postrecurrence survival are recommended.

Original languageEnglish
Pages (from-to)1936-1942
Number of pages7
JournalCancer
Volume100
Issue number9
DOIs
Publication statusPublished - May 1 2004

Keywords

  • Bcl-2
  • HER-2/ErbB-2
  • Metastasis
  • Osteosarcoma
  • P-glycoprotein
  • p53

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Evaluation of P-Glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in Primary Tumor and Metachronous Lung Metastases in Patients with High-Grade Osteosarcoma'. Together they form a unique fingerprint.

Cite this